Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Treatment Strategies for Psychological Disorders

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Experiences of restrictive practices in child and adolescent mental health inpatient care: an integrative review.

Child and adolescent psychiatry and mental health·2026

Same author

1390 nm GaAs-based dilute nitride VCSELs on 150 mm wafers for scalable production.

Optics express·2026

Same author

Topographical memory in transient epileptic amnesia.

Epilepsy & behavior : E&B·2026

Same author

Co-production as the ultimate goal; an incentive or discouragement?

Research involvement and engagement·2025

Same author

Evidence of Genetic Isolation and Differentiation Among Historically Fragmented British Populations of Common Juniper, <i>Juniperus communis</i> L.

Ecology and evolution·2025

Same author

Author Correction: Electrical stimulation of smiling muscles reduces visual processing load and enhances happiness perception in neutral faces.

Communications psychology·2025

Search research articles

Related Experiment Video

Updated: Sep 24, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

AD and its comorbidities: An obstacle to develop a clinically efficient treatment?

J Baker¹, J M Schott¹

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.

Revue Neurologique

|May 6, 2022

Summary

Alzheimer's disease (AD) treatments face challenges due to comorbidities often excluded from trials. Adapting clinical trials to include these conditions is crucial for developing effective AD therapies.

Keywords:

Alzheimer's disease Clinical trials Comorbidities Neuropathology Neuropharmacology

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Related Experiment Videos

Last Updated: Sep 24, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Area of Science:

Neuroscience
Pharmacology
Clinical Trials

Background:

Alzheimer's disease (AD) lacks treatments proven to slow progression.
Regulatory divergence (FDA vs. EMA) on aducanumab highlights efficacy and safety concerns.
Comorbidities are common in AD patients but often excluded from clinical trials.

Purpose of the Study:

To discuss the impact of comorbidities on Alzheimer's disease (AD) treatment development.
To examine evolving definitions of AD and common comorbid conditions.
To analyze how comorbidity exclusion/inclusion affects AD trials and real-world therapeutic use.

Main Methods:

Literature review and discussion of AD definitions and comorbidities.
Analysis of the implications of comorbidity exclusion in clinical trials.
Examination of the impact of comorbidities on the real-world application of AD therapeutics.

Main Results:

Definitions of Alzheimer's disease (AD) continue to evolve.
Several comorbidities frequently accompany or mimic AD.
Exclusion of comorbidities from trials may limit the generalizability of treatment efficacy and safety findings.

Conclusions:

Comorbidities significantly complicate Alzheimer's disease (AD) treatment development.
Clinical trial designs may need adaptation to better reflect the complexities of AD patients.
Future research should consider the impact of comorbidities for more effective AD therapeutics.